Myriad Genetics, Inc. (MYGN) said it expects fourth quarter total revenues to be between $207 million and $209 million. Full year 2025 total revenues are projected to be between $822 million to $824 million. The company plans to release its actual financial results for the fourth quarter during its earnings call to be held in February 2026.
For full year 2026, the company projects: revenue in a range of $860 - $880 million, and adjusted EBITDA in a range of $37 - $49 million.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.